
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
| Publishes | Monthly | Episodes | 359 | Founded | 20 years ago |
|---|---|---|---|---|---|
| Number of Listeners | Categories | ScienceHealth & FitnessMedicine | |||

Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and... more
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-st... more
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.
CME information and select publications here.
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer.
CME information and select publications here.
People also subscribe to these shows.




Third year medicine resident applying to Heme onc fellowship. I am interested in lung cancer and this podcast inspires critical thinking about patient management and provokes thought about the lung cancer literature. Uniquely has fantastic interviews with experts in the field. A great listen. I recommend this to anyone interested in oncology and interested in improving their knowledge of lung cancer management.
Hier ben ik heel blij mee.
Ik wou dat zoiets in het Nederlands bestond.
Key themes from listener reviews, highlighting what works and what could be improved about the show.
How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.
Apple Podcasts | #41 |
Recent interactions between the hosts and their guests.
Listeners, social reach, demographics and more for this podcast.
| Listeners per Episode | |
|---|---|
| Gender Skew | |
| Location | |
| Interests | |
| Professions | |
| Age Range | |
| Household Income | |
| Social Media Reach |
The content primarily revolves around the latest advancements in lung cancer research and treatments, featuring expert insights from leading oncologists and researchers. It addresses a wide range of topics, including small cell lung cancer, non-small cell lung cancer, immunotherapy, targeted therapies, and the complexities of treatment regimens tailored for patients with specific mutations. What sets this series apart is its focus on bridging the gap between cutting-edge research and practical applications in patient care, making it especially beneficial for medical professionals seeking to enhance their clinical practice with the latest findings.
Rephonic provides a wide range of podcast stats for Lung Cancer Update. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Lung Cancer Update and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.
Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Lung Cancer Update, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.
Rephonic provides comprehensive predictive audience data for Lung Cancer Update, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.
To see how many followers or subscribers Lung Cancer Update has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.
These podcasts share a similar audience with Lung Cancer Update:
1. Gastrointestinal Cancer Update
2. Lung Cancer Considered
3. Breast Cancer Update
4. Prostate Cancer Update
5. Oncology Today with Dr Neil Love
Lung Cancer Update launched 20 years ago and published 359 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.
Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.
Rephonic pulls ratings and reviews for Lung Cancer Update from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.
View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.
Rephonic provides full transcripts for episodes of Lung Cancer Update. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.
Recent guests on Lung Cancer Update include:
1. Hossein Borghaei
2. Anne Chiang
3. Aaron Lisberg
4. Dr. Aaron Lisberg
5. Dr. Jacob Sands
6. Ben Levy
7. Dr. Justin Gainor
8. Dr. Edward Garon
To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.